Stelara (Ustekinumab) Insurance Denial Appeal Guide

Stelara (ustekinumab) treats moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. With biosimilars entering the market in 2025, coverage is shifting and denials may increase.

Indications

Moderate-to-severe plaque psoriasis (adults and pediatric 6+)
Active psoriatic arthritis
Moderate-to-severe Crohn's disease
Moderate-to-severe ulcerative colitis

Common Denial Reasons

Biosimilar available (2025 launches)
Step therapy (TNF inhibitors required first)
Non-formulary
Prior authorization documentation gaps

Appeal Strategy

Document failure of TNF inhibitors (if required by step therapy)
Cite unique IL-12/23 mechanism (different from TNF inhibitors)
If stable on Stelara, cite switching risks
Reference ACR, NPF, or ACG guidelines
Convenient dosing schedule (every 8-12 weeks) aids adherence

Need Help Writing Your Appeal?

Our AI-powered tool analyzes your denial letter and generates a personalized appeal in minutes. Upload your denial and get started for free.

Start Your Free Appeal

Frequently Asked Questions

Are there Stelara biosimilars?

Yes, Stelara biosimilars began entering the U.S. market in 2025. Your insurer may require you to try a biosimilar before or instead of brand Stelara. If you're currently stable on Stelara, work with your doctor to request a formulary exception.